PARP1 and breast cancer: Consistent with these results, PARP-1, a downstream target of caspase-3, was also cleaved in both ascites-derived BC-3 and BCBL-1 cells 48 h post treatment with the combination of ATO/Lena (Figure 4), indicating the induction of apoptosis.